2024 has been an exciting year for Genialis as we continue to make strides in precision oncology. This year, our work in RNA biomarkers earned recognition from some of the most respected awards programs in the field. Here’s how we stood out:
Winning the Biomarker Discovery Platform of the Year Award
Genialis was awarded the title Biomarker Discovery Platform of the Year by the BioTech Breakthrough Awards program. This award recognizes platforms that improve biomarker discovery and implementation. Our first-in-class patient classifier, Genialis™ krasID, stood out for its ability to use RNA-seq data and machine learning to predict clinical benefit and treatment response to KRAS inhibitors. By addressing key challenges in drug development, Genialis krasID helps researchers make informed decisions, reduce risks, and improve patient outcomes.
Biotech Innovation Award finalist at Biotech Week Boston
In addition to our win, Genialis was named a finalist for the Biotech Innovation Award at Biotech Week Boston. This recognition celebrates advancements in biopharmaceutical products, processes, and technologies. Our nomination spotlighted the role of RNA biomarkers and machine learning in transforming cancer research. Being named a finalist underscores the value of our contributions to guiding treatment strategies and advancing precision medicine.
Finalist in the Fierce Life Sciences Innovation Awards
Genialis was also recognized as a finalist in the Fierce Life Sciences Innovation Awards. This program, which introduced a new AI Innovation category in 2024, highlights advancements that reshape drug development, clinical research, and patient care. Our AI-powered RNA biomarkers earned this recognition for their potential to streamline clinical trials, cut costs, and improve outcomes.
Building on our success
These recognitions are more than just milestones – they reflect our ongoing mission to make precision oncology work for every target, drug, and patient.
To our team, partners, and customers, thank you for being part of this journey. Stay connected with us on LinkedIn as we continue to share our progress and explore new opportunities to transform medicine through data.